Aarti Drugs Limited

NSEI:AARTIDRUGS Stock Report

Market Cap: ₹39.5b

Aarti Drugs Future Growth

Future criteria checks 4/6

Aarti Drugs is forecast to grow earnings and revenue by 31.5% and 13.4% per annum respectively. EPS is expected to grow by 31.5% per annum. Return on equity is forecast to be 17.7% in 3 years.

Key information

31.5%

Earnings growth rate

31.5%

EPS growth rate

Pharmaceuticals earnings growth17.3%
Revenue growth rate13.4%
Future return on equity17.7%
Analyst coverage

Low

Last updated25 Oct 2024

Recent future growth updates

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Feb 01
Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Recent updates

We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Sep 20
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Sep 05
Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

May 04
Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Feb 01
Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Jan 30
Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

May 17
Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

Nov 22
These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet

Aug 28
We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet

Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching

Aug 19
Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching

Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value

May 17
Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value

Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock

Apr 04
Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock

Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?

Mar 17
Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Mar 02
Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?

Feb 17
What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?

Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio

Feb 04
Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio

What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?

Jan 22
What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?

Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth

Jan 07
Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth

If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late

Dec 23
If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late

Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly

Dec 08
Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Nov 23
Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?

Nov 08
How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?

Earnings and Revenue Growth Forecasts

NSEI:AARTIDRUGS - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202732,6123,1071,4432,9431
3/31/202628,6952,4677732,2731
3/31/202524,5601,5611,3153,3151
9/30/202423,7961,5221,0193,082N/A
6/30/202424,2281,568N/AN/AN/A
3/31/202425,2861,7141,3263,589N/A
12/31/202326,5101,802N/AN/AN/A
9/30/202327,0901,8021,2133,171N/A
6/30/202327,5521,794N/AN/AN/A
3/31/202327,1611,663-3151,333N/A
12/31/202226,6791,656N/AN/AN/A
9/30/202226,3871,872-836700N/A
6/30/202225,3061,910N/AN/AN/A
3/31/202224,8862,050-816704N/A
12/31/202122,9612,014N/AN/AN/A
9/30/202121,9162,1111371,322N/A
6/30/202121,9012,438N/AN/AN/A
3/31/202121,5482,8046671,550N/A
12/31/202021,0272,876N/AN/AN/A
9/30/202020,4592,4741,3382,070N/A
6/30/202019,4532,044N/AN/AN/A
3/31/202018,0611,4142,0282,507N/A
12/31/201918,1561,100N/AN/AN/A
9/30/201917,2221,031N/AN/AN/A
6/30/201915,921888N/AN/AN/A
3/31/201915,6098986881,431N/A
12/31/201814,136863N/AN/AN/A
9/30/201813,689887N/AN/AN/A
6/30/201813,407943N/AN/AN/A
3/31/201812,436823N/A698N/A
12/31/201711,592790N/AN/AN/A
9/30/201711,340735N/AN/AN/A
6/30/201711,569721N/AN/AN/A
3/31/201711,952818N/A1,748N/A
12/31/201612,102785N/AN/AN/A
9/30/201611,856776N/AN/AN/A
6/30/201611,431713N/AN/AN/A
3/31/201611,349687N/A1,333N/A
12/31/201511,101686N/AN/AN/A
9/30/201511,047744N/AN/AN/A
6/30/201511,180774N/AN/AN/A
3/31/201510,943773N/A1,046N/A
12/31/201410,868807N/AN/AN/A
9/30/201410,490721N/AN/AN/A
6/30/201410,109662N/AN/AN/A
3/31/20149,699608N/A954N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AARTIDRUGS's forecast earnings growth (31.5% per year) is above the savings rate (6.7%).

Earnings vs Market: AARTIDRUGS's earnings (31.5% per year) are forecast to grow faster than the Indian market (18% per year).

High Growth Earnings: AARTIDRUGS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AARTIDRUGS's revenue (13.4% per year) is forecast to grow faster than the Indian market (10.7% per year).

High Growth Revenue: AARTIDRUGS's revenue (13.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AARTIDRUGS's Return on Equity is forecast to be low in 3 years time (17.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/11 23:08
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aarti Drugs Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rashmi Sancheti ShettyCGS International
Rashmi Sancheti ShettyDolat Capital Market Pvt. Ltd.
Kameswari V. S. ChavaliFirstCall Research